Cambridge Sleep Sciences and Parkinson’s Concierge have entered an agreement to tackle sleep problems in Parkinson’s disease. Sleep problems such as difficulty falling asleep, daytime sleepiness, and troubled dreams are among the most common non-motor symptoms of Parkinson’s disease. Sleep also can be indirectly affected by other…
In Parkinson’s disease, iron accumulates in certain parts of the brain that have characteristic genetic profiles, according to a new study. This finding may help to explain the biological processes that cause Parkinson’s, which could be important for developing treatments. The study, “Regional brain iron…
The Parkinson’s Foundation has announced that this year’s Moving Day walk season will include virtual and contactless events. Moving Day, which is the Foundation’s signature fundraising event, aims to increase awareness about Parkinson’s disease, as well as raise money that will fund research and provide expert care for…
People with a sleep disorder marked by the physical “acting out” of vivid dreams — a condition considered an early form of Parkinson’s disease — show changes in specific immune cells in the blood that directly relate to inflammation and damage to dopamine neurons in the brain, researchers…
People with type 2 diabetes may have an increased risk of developing Parkinson’s disease and for experiencing faster Parkinson’s progression, according to a large-scale analysis of past research. The study, “Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression,” was published in the…
ANVS401, an investigational therapy for neurodegenerative diseases being developed by Annovis Bio, improved the speed and coordination of people with Parkinson’s disease in a Phase 2a clinical trial, an interim analysis suggests. “The results from this interim analysis are very encouraging. This brings us one step closer to…
Newron Pharmaceuticals and Zambon Pharma agreed to jointly support a potentially pivotal clinical trial of Xadago (safinamide) as a treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. Under the terms of the agreement, Newron and Zambon will evenly share the cost of the intended study. Newron, which developed…
Researchers at the Sheffield Institute for Translational Neuroscience (SITraN) have been awarded £1.2 million ($1.67 million) from Parkinson’s UK to develop new treatments that slow progression of the disease. “This new funding will greatly accelerate the project and shows our commitment to working with ground-breaking academic researchers in the UK…
People with Parkinson’s disease have substantial changes in the bacteria living in their gut relative to people without this neurodegenerative disorder, an analysis underscores. “This dysbiosis [microbial imbalance] might result in a pro-inflammatory status which could be linked to the recurrent gastrointestinal symptoms affecting PD [Parkinson’s disease] patients,” its…
Three Canadian research centers and one drug discovery firm are collaborating to design new medicines to treat levodopa-induced dyskinesia in Parkinson’s disease, according to a press release. Nearly all people with Parkinson’s receive levodopa to treat the movement difficulties caused by the body’s loss of its own…
Get regular updates to your inbox.